
Special Interests
- Bioinformatics
- Immunotherapy
- Laser thermotherapy (LITT)
- Tumor Microenvironment
- Nanotechnology
Dr. Ravi Kumar is an Assistant Scientist in the Lillian S. Wells Department of Neurosurgery at the University of Florida College of Medicine. He is a member of the Translational Brain Tumor Immunotherapy Laboratory, led by Dr. Maryam Rahman, MD, MS. His research focuses on developing innovative therapeutic approaches for glioblastoma (GBM) and brain metastases by integrating nanomedicine, cancer immunotherapy, bioinformatics, and advanced preclinical models.
Dr. Kumar earned his PhD in Nanoscience and Nanotechnology from Jawaharlal Nehru University (JNU), New Delhi, in 2021. His doctoral research focused on the synthesis, surface modification, and characterization of magnetic nanomaterials for biomedical applications, particularly cancer treatment using magnetic hyperthermia. He subsequently worked on developing giant magnetoresistance (GMR)-based biosensors for early cancer detection, further expanding his expertise at the interface of nanotechnology and cancer research.
Dr. Kumar joined the University of Florida as a Postdoctoral Associate under the mentorship of Dr. Rahman, where he transitioned into translational brain tumor research. His work involves developing and evaluating novel therapeutic strategies that combine laser interstitial thermal therapy (LITT) with immunotherapy and nanomedicine-based approaches. He has gained extensive experience in murine brain tumor models, including stereotactic LITT, immune profiling, and the investigation of treatment-induced changes in the tumor microenvironment.
A major focus of his current research is understanding how therapeutic interventions influence antitumor immunity and the interactions between tumor cells and their surrounding immune microenvironment. His work includes investigating LITT in combination with immune checkpoint inhibitors and evaluating strategies to improve drug delivery and therapeutic responses in brain tumors.
Another major area of his research involves the development and evaluation of a novel microgel–chemokine mRNA (MCM) vaccine platform that delivers tumor-derived mRNA antigens to stimulate antitumor immune responses against glioblastoma. His work explores how this immunotherapeutic approach influences immune cell recruitment, activation, and interactions within the tumor microenvironment, with particular interest in the roles of T cells, macrophages, and microglia.
In addition to his experimental research, Dr. Kumar has developed expertise in bioinformatics and transcriptomic analysis, particularly bulk and single-cell RNA sequencing. His research involves identifying immune cell populations, characterizing their functional states, and investigating molecular pathways associated with treatment responses. He also contributes to translational studies associated with the TORCH clinical trial, which investigates LITT in combination with pembrolizumab for recurrent brain metastases.
By combining his multidisciplinary background in nanotechnology, cancer biology, immunology, and computational biology, Dr. Kumar aims to better understand the mechanisms underlying brain tumor progression and treatment resistance and contribute to the development of more effective, clinically translatable therapies for patients with malignant brain tumors.